Monday , April 22 2019
Home / Project Syndicate / An Earnest Proposal for Tackling AMR

An Earnest Proposal for Tackling AMR

Summary:
Despite global recognition of the threat posed by antimicrobial resistance (AMR), not nearly enough has been done to bring new antibiotics into development. With some drug makers now leaving the antibiotics market altogether, there is an urgent need for a realignment of incentives in this vital area of public health. LONDON – Under Article 50 of the Treaty of Lisbon, the United Kingdom will leave the European Union on March 29, 2019. Presuming that it does (but even if it does not), the UK government should continue to lead the charge against antimicrobial resistance (AMR), as it has in the past. Specifically, it is time for the UK to join with pharmaceutical companies in piloting a new model of finance for investment in research and

Topics:
Jim O'Neill considers the following as important:

This could be interesting, too:

Bradford DeLong writes Brad DeLong's Grasping Reality 2019-04-22 03:59:17

Bradford DeLong writes Brad DeLong's Grasping Reality 2019-04-22 03:47:47

Frances Woolley writes About that EKOS poll

Bradford DeLong writes Brad DeLong's Grasping Reality 2019-04-22 02:34:31

Despite global recognition of the threat posed by antimicrobial resistance (AMR), not nearly enough has been done to bring new antibiotics into development. With some drug makers now leaving the antibiotics market altogether, there is an urgent need for a realignment of incentives in this vital area of public health.

LONDON – Under Article 50 of the Treaty of Lisbon, the United Kingdom will leave the European Union on March 29, 2019. Presuming that it does (but even if it does not), the UK government should continue to lead the charge against antimicrobial resistance (AMR), as it has in the past. Specifically, it is time for the UK to join with pharmaceutical companies in piloting a new model of finance for investment in research and development of new antibiotics.

Over the course of my professional life, one of the most rewarding roles that I ever had was between late 2014 and September 2016, when I chaired an independent Review on AMR under the...

Leave a Reply

Your email address will not be published. Required fields are marked *